Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 5/20 | 0.57 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.56 |
| ▸ | ELANE | P08246 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 6/20 | 0.54 |
| ▸ | CTSL | P07711 | 5/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268187 | 1.00 | ATM (0.59) | ATMCYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1547277 | 1.00 | ATM (0.59) | ATMCYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15414625 | 0.88 | ATM (0.57) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL938009 | 0.88 | ATM (0.57) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL938011 | 0.88 | ATM (0.57) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL13770419 | 0.87 | CASP3 (0.58) | CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13572927 | 0.87 | ATM (0.59) | ATMCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13534727 | 0.87 | NPC1 (0.65) | ATMALDH1A1LMNACTSKCTRB1 | |
| SCHEMBL6407665 | 0.87 | ATM (0.59) | ATMCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14999596 | 0.87 | ATM (0.59) | ATMCYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025019172-A1 | ANTIMICROBIAL EXTRACTANT FORMED FROM COPPER-CONTAINING SOURCE | CORNING INCORPORATED (US) | 2025-01-23 | — | — | WO | claimed |
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-05-14 | — | — | US | disclosed |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2026090104-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260092038-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| EP-4031542-B1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2025-08-07 | — | — | US | disclosed |
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-111148739-B | Cyclic peptide antibiotics | 豪夫迈·罗氏有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1278502-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001089451-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6214829-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2001-04-10 | — | — | US | disclosed |
| EP-0900792-A1 | Piperazine and piperidine derivatives as 5-HT1 receptor agonists | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1999-03-10 | — | — | EP | disclosed |
| US-5688823-A | ANTILIPEMIC AGENTS, ANTIGLYCEMIC AGENTS, OBESITY, GLUCOSE TOLERANCE INSUFFICIENCY, INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1997-11-18 | — | — | US | disclosed |
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |
| US-3971822-A | Aspartyl amide sweetening agents | TANABE SEIYAKU CO., LTD. (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | ATM 2968/4885CYP3A4 1597/4885CYP1A2 1105/4885 |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNNA1, CTNND1 | ATM 4266/4885CYP3A4 2366/4885CYP1A2 3433/4885 |
| US-20260092038-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | ATM 2937/4885CYP3A4 1408/4885CYP1A2 1384/4885 |
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | TRHR, NR3C2, THRB | ATM 2868/4885CYP3A4 4152/4885CYP1A2 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.